Dice CEO: Energy, T...
Health Care: Health Services
Enzo Biochem Inc. (ENZ: NYSE)
$1.79 -0.03 | -1.65%
06/01/12 - 04:03 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 70.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 88.50 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 21.80 | 12.50 |
| Beta | 1.71 | 0.68 | 0.98 |
| Price to Sales (TTM) | 0.67 | 1.54 | 1.42 |
| Price to Book (MRQ) | 0.88 | 2.30 | 2.41 |
| Price to Tangible Book (MRQ) | 2.06 | -8.10 | 5.08 |
| Price to Cash Flow (TTM) | -6.70 | 15.00 | 9.80 |
| Price to Free Cash Flow (TTM) | -6.30 | 54.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.60 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.40 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | -2.58 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 88.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 5.20 | 12.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 5.10 | 2.90 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 16.93 | 15.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -0.70 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -0.70 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | -13.79 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -28.02 | 9.33 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.90 | 1.20 | 1.10 |
| Current Ratio (MRQ) | 2.60 | 1.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.70 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.80 | 0.96 |
| Interest Coverage (TTM) | n.a. | 2.60 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 50.60 | 45.20 | 46.90 |
| Gross Margin - 5 Yr Avg | 50.70 | 45.50 | 47.70 |
| EBITD Margin (TTM) | -9.60 | 17.80 | 18.90 |
| EBITD - 5 Yr Avg | -11.97 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -14.10 | 3.70 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -19.70 | 11.30 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.14 | 0.01 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -19.70 | 6.10 | 7.00 |
| Return on Assets (TTM) | -15.00 | 0.60 | 3.10 |
| Return on Assets - 5 Yr Avg | -12.30 | 4.80 | 2.50 |
| Return on Investment (TTM) | -18.00 | 0.90 | 7.90 |
| Return on Investment - 5 Yr Avg | -14.20 | 6.60 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 193,213.00 | 213,809.00 | 449,376.00 |
| Net Income/Employee (TTM) | -27,753.00 | 1,800.00 | 39,003.00 |
| Receivable Turnover (TTM) | 8.00 | 5.70 | 7.60 |
| Inventory Turnover (TTM) | 5.50 | 23.30 | 8.30 |
| Asset Turnover (TTM) | 1.00 | 0.80 | 0.40 |
Portfolios with ENZ
- Portfolio NameUser Type
- UserBarron's Insider Purchases ...
- ContributorStockerblog.com Gene Therap...
- Userkelvinenz Portfolio 1
- UserS-0022
- UserTraderSteveUK Portfolio 1
- UserRT_in_CA
- UserSo far, I'm beating the S&a...
- Userjwcarmack Portfolio 1
- Userrecentoutperform070824
- Usersfields Portfolio 1
Latest ENZ Headlines from TheStreet
- Thursday Earnings Live Blog 10.14.10 | 04:10 pm
- Investors May See Upside Down Under 09.16.10 | 08:09 am
- Enzo Biochem 1Q Loss Narrows On Revenue Boost 12.10.09 | 04:12 pm
- Enzo Biochem 4Q Loss Widens On Costs 10.14.09 | 06:10 pm
- Tuesday's Health Winners & Losers 10.16.07 | 04:10 pm
- Enzo Biochem Falls on Court Dismissal 09.07.07 | 02:09 pm
- Friday's Health Winners & Losers 09.07.07 | 02:09 pm
- Checking Up on Biotech 08.10.07 | 04:08 pm
- Monday's Health Winners & Losers 10.16.06 | 02:10 pm
- Enzo Biochem Loss Widens 10.16.06 | 11:10 am
Press Releases for ENZ
- Enzo Biochem Launch Of Test For Measuring Risk Of Colorectal Cancer Underscores Growing Role Of Molecular Diagnostics - Business Wire 04.10.12 | 08:04 am
- Enzo Biochem Presents New AmpiProbe™ Nucleic Acid Amplification Platform Details At ESCMID London Meeting - Business Wire 04.01.12 | 04:04 pm
- Enzo Biochem To Present At Needham Healthcare Conference - Business Wire 03.27.12 | 12:03 pm
- Enzo Biochem Announces Expanded Distribution Agreement With Japan’s Cosmo Bio - Business Wire 03.20.12 | 07:03 am
- Enzo Biochem’s Clinical Laboratory Applies For NY State Health Department Approval For First Assay Based On Its AmpiProbe™ Amplification Platform - Business Wire 03.13.12 | 07:03 am
- Enzo Biochem Reports Improved Second Quarter Results - Business Wire 03.12.12 | 04:03 pm
- Enzo Biochem To Present New AmpiProbe™ Nucleic Acid Amplification Platform At ESCMID London Meeting - Business Wire 03.08.12 | 08:03 am
- Enzo Biochem Schedules Teleconference To Discuss 2012 Second Quarter Results On March 13, 2012 At 8:30 AM E.T. - Business Wire 03.08.12 | 07:03 am
- Enzo Biochem Receives Approval For Novel Blood Based Test For Colorectal Cancer Risk - Business Wire 02.21.12 | 08:02 am
- Enzo Biochem To Present At 2012 Leerink Swann Global Healthcare Conference - Business Wire 02.10.12 | 12:02 pm
Partner Headlines for ENZ
- Investors Should Wait Out Quest & LabCorp - Seeking Alpha 02.16.12 | 09:02 am
- Enzo Biochem: Personalized Medicine Is More Than Targeted Therapeutics - Seeking Alpha 04.03.11 | 07:04 am
- Competitive Technologies: Short Squeeze Coming or Another Leg Down? - Seeking Alpha 08.25.10 | 09:08 am
- Top 5 Percentage Gainers On NYSE (DV, CKH, ENZ, LAD, CMG) - Benzinga 07.23.10 | 03:07 pm
- MB FINANCL INC (MBFI) - Profit Tracks - Zacks 04.13.10 | 01:04 am
- UPDATE 2-Enzo wins round in Applera patent fight - Reuters 03.26.10 | 04:03 pm
